Findings from a recent study showed patients with hidradenitis suppurativa may have an increased risk of developing cancer, including Hodgkin lymphoma and nonmelanoma skin cancer.

Findings from a recent study indicated that several comorbidities precede a diagnosis of hidradenitis suppurativa, and that several develop afterwards.

Findings from an open label cohort study showed treatment of moderate to severe hidradenitis suppurativa with an IL-17 inhibitor was associated clinical response and had a favorable safety profile.

Findings from a recent study showed that satisfaction with physicians is associated with mental health comorbidities among patients with psoriasis.

Understanding the dermatologic signs of COVID-19 will help elucidate whether pernio-toes, papulovesicular lesions, retiform purpura, or another underreported manifestation are legitimate diagnostic features of the disease.

Guidance Released on the Management of Cutaneous Lymphoma During the Pandemic; The Skin Cancer Foundation Awards Research Grants; Minority Populations Less Aware of Melanoma; Childhood BMI Significantly Associated with HS Risk

A recent meta-analysis and systematic review investigated the effectiveness of systemic treatments for patients with atopic dermatitis, highlighting 2 with potentially better short-term efficacy.

Findings from a recent study showed a potential association between birth weight and childhood weight and the risk of developing hidradenitis suppurativa in adulthood.

A recent study investigated the efficacy of ixekizumab for the treatment of moderate to severe pityriasis rubra pilaris, which showed promising results for the inhibition of IL-17 in this disease.

Findings from a recent study showed no association between the use of topical tacrolimus and cancer among pediatric patients with atopic dermatitis.